Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.

Ther Adv Neurol Disord · 2025 · PMC12317234 · PMID 40756532

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

A notable trend toward reduction was observed after 24 months of CladT treatment, with the KFLC index decreasing to a mean ± SD of 37.08 ± 30.21 (range: 6.22–91.99; Figure 4(b) ).

also in 2,155 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.